Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

Share Price is delayed by 15 minutes
Get Live Data
1,078.50    26.00 (2.47%)
Bid:
1,071.00
Ask:
1,072.00
Spread: 1.00 (0.093%)
Market Cap: £3.46b
PSN Live PriceLast checked at - London Stock Exchange

Intraday Persimmon Share Chart

Interim Management Statement

16 Apr 2014 07:00

RNS Number : 9142E
Persimmon PLC
16 April 2014
 



INTERIM MANAGEMENT STATEMENT

 

WEDNESDAY 16 APRIL 2014

 

 

Persimmon plc ("the Company") will hold its Annual General Meeting ("AGM") at 12.00 noon today at York Racecourse when the Chairman will make the following statement regarding current trading, financial performance and the outlook for the current financial year. This statement covers the period from 1 January 2014 to date and supplements the update given with the 2013 Final Results on 25 February 2014.

 

The new financial year has started well with visitor levels to our sites up 10% over the prior year during the initial fifteen weeks of trading. Cancellation rates over this period of 14% continue to run at historically low levels (2013: 15%).

 

Our weekly private sales rate per site for the first fifteen weeks of 2014 was 25% ahead of the prior year. Together with the strong sales position brought forward into the new year, this improved rate of sale results in current total forward sales of £1.87 billion for 2014, which includes legal completions taken so far this year. Total forward sales revenue is 35% higher than in 2013 (£1.38 billion). We have c.7,200 new homes sold forward into the private sale market for 2014 which is 38% ahead of the same point last year, with an average selling price of c.£200,400 which is c.3% higher.

 

We currently have c.395 active sites across the UK and have successfully opened 75 of the 90 new outlets targeted for the first half of 2014 to refresh this network. Our build activity continues to support the improved rates of sale and we remain confident of delivering further growth in the number of new homes legally completed for 2014.

 

The Government sponsored Help to Buy shared equity scheme in England reached its first anniversary on 1 April 2014 and we have now sold c.5,000 new homes to customers using mortgages associated with this scheme, of which 2,203 legally completed in 2013. In addition, we have sold a further c.600 new homes in Scotland and Wales to customers using similar mortgage products in these regional markets.

 

The recently announced extension of Help to Buy from March 2016 to March 2020 provides welcome support to potential new home purchasers for this additional four year period. As a consequence, and with the support of the mortgage lending industry, housebuilders have the opportunity to continue to increase the industry's development commitments in support of increasing the number of new homes delivered to the market over the medium term.

 

Our strategy remains focussed on exercising capital discipline through the cycle whilst growing the business as market conditions allow. Our commitment to return c.£1.9 billion of surplus capital to shareholders over the period to 2021 is a key feature of this capital discipline. In the Final Results statement on 25 February 2014 the Directors announced a further acceleration of this programme of capital return. Subject to shareholder approval at the AGM, the second payment of the Capital Return Plan of c.£213 million, or 70p per share, will be paid to shareholders on 4 July 2014. This 70p per share payment is a part acceleration of the 115p final payment originally planned for 2021. The record date is 6.00 p.m. on 4 June 2014 and the shares trade ex-entitlement from 8.00 a.m. on 5 June 2014.

 

In line with the approach adopted with the first payment under the Capital Return Plan in 2013, the Directors will offer shareholders the opportunity, where possible, to choose to receive the cash either as a return of capital or as dividend income by way of a B / C share scheme. Full details of the B / C share proposal have been sent to shareholders with the notice of the Company's AGM. The closing date for elections to be made by shareholders is 11.00 a.m. on 20 June 2014.

 

The Directors are pleased to announce that the Company has recently concluded an amendment of its £300 million Revolving Credit Facility with the Company's five relationship banks. The new facility has been extended to a maturity date of 31 March 2019.

 

We will provide a further report on progress in our Trading Update on Wednesday 2 July 2014.

 

For further information please contact:-

 

Jeff Fairburn, Group Chief Executive

Simon Rigby

Mike Killoran, Group Finance Director

Kevin Smith

Persimmon plc

Lindsay Noton

Tel: +44 (0) 20 7638 9571 on the day

Citigate Dewe Rogerson

Tel: +44 (0) 1904 642199 thereafter

Tel: +44 (0) 20 7638 9571

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUVANRSKASAAR
Date   Source Headline
1st May 20257:00 amRNSAGM Trading Statement
25th Apr 202510:54 amRNSHolding(s) in Company
25th Apr 20259:24 amRNSHolding(s) in Company
11th Apr 20254:22 pmRNSHolding(s) in Company
3rd Apr 202510:15 amRNSHolding(s) in Company
2nd Apr 202512:22 pmRNSHolding(s) in Company
1st Apr 202512:03 pmRNSTotal Voting Rights
31st Mar 20253:14 pmRNSDirector/PDMR Shareholding
27th Mar 202510:08 amRNSHolding(s) in Company
25th Mar 20253:14 pmRNSDirector/PDMR Shareholding
24th Mar 20253:35 pmRNSAnnual Report 2024 and Notice of AGM 2025
24th Mar 20252:24 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSFull Year Results
6th Mar 20252:06 pmRNSHolding(s) in Company
3rd Mar 20253:35 pmRNSHolding(s) in Company
3rd Feb 202512:26 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNS2024 Trading Statement
2nd Jan 20251:00 pmRNSTotal Voting Rights
10th Dec 20243:47 pmRNSDirectorate Change
2nd Dec 20242:11 pmRNSBlock listing Interim Review
2nd Dec 202412:00 pmRNSTotal Voting Rights
6th Nov 20247:00 amRNSQ3 Trading Statement
5th Nov 20241:31 pmRNSHolding(s) in Company
1st Nov 20243:59 pmRNSTotal Voting Rights
1st Oct 20241:19 pmRNSTotal Voting Rights
24th Sep 202412:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20241:44 pmRNSTotal Voting Rights
8th Aug 20247:00 amRNSHalf Year Results
1st Aug 20242:32 pmRNSTotal Voting Rights
23rd Jul 202410:28 amRNSDirectorate Change
1st Jul 20241:10 pmRNSTotal Voting Rights
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.